– Ziva Cooper, Ph.D. and Mallory Loflin, Ph.D. become latest
members of the renowned group of FSD Scientific Advisors led by Charles
Pollack, Jr. MD, FACEP

TORONTO–(BUSINESS WIRE)–#FSDDF–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the
“Company”), is pleased to announce the addition of two
distinguished cannabis researchers to the company’s Scientific Advisory
Board (“SAB”).

“It is with great pride that we welcome Dr. Ziva Cooper and Dr. Mallory
Loflin to our Scientific Advisory Board. The board, which also includes
Dr. Daniel Piomelli and Dr. Ryan Vandrey, is shaping into a very robust
body of scientists and researchers under the leadership of my good
friend Dr. Pollack and I commend him for his leadership. We are counting
on the invaluable input of our SAB members as we continue to explore the
value add of potential applications of medicinal grade cannabis and
synthetic cannabinoid pharmaceuticals,” said Dr. Raza Bokhari, FSD
Executive Co-Chairman & Chief Executive Officer.

Ziva Cooper, Ph.D., is the Research Director of UCLA’s Cannabis Research
Initiative in the Semel Institute for Neuroscience and Human Behavior in
the Department of Psychiatry and Biobehavioral Sciences. Dr. Cooper has
been overseeing and publishing studies investigating cannabis
neurobiology and dependence for over 10 years, including studies
examining the effects of these drugs on experimentally induced
pain. After receiving her Ph.D. in Biopsychology in 2007 in the field of
preclinical psychopharmacology, she moved to Columbia University to
focus on translating preclinical studies of psychoactive substances to
the clinic using controlled human drug-administration studies. Dr.
Cooper’s current research involves understanding the neurobiological,
pharmacological, and behavioral variables that influence both the
therapeutic potential and adverse effects of cannabis and cannabinoids.
She previously served on the National Academies of Sciences Committee on
the Health Effects of Cannabis that recently published a comprehensive
consensus report of the health effects of cannabis and cannabinoids. Dr.
Cooper is a member of the Editorial Board of Cannabis and
Cannabinoid Research.

Mallory Loflin, Ph.D., is a research scientist for Veterans Affairs San
Diego Healthcare System (VASDHCS) and an Assistant Professor of
Psychiatry within the University of California, San Diego (UCSD) School
of Medicine. Dr. Loflin’s entire research career has been dedicated to
the study of cannabinoids, with the aim of informing both prevention
efforts for problematic use and development of cannabinoid-based
therapeutics. She is currently conducting as Principal Investigator
(PI) the first VA-funded cannabinoid clinical trial, “Cannabidiol as an
Adjunctive to Prolonged Exposure for the Treatment of PTSD,” as part of
a Career Development Award (CDA-2) funded by VA Clinical Science
Research & Development (CSR&D). Dr. Loflin is also a co-investigator and
consultant on four other ongoing cannabis and cannabinoid research
studies, and currently holds a DEA research registration for schedule 1
controlled substances at VA San Diego. She is currently engaged in
training efforts for advanced specialization in private-public drug
development as part of her CDA-2 award’s training plan.

The SAB is led by Chairman Charles V. Pollack, Jr., M.A., M.D., FACEP,
FAAEM, FAHA, FACC, FESC, FCPP, an international leader in emergency
medicine and founder of The Lambert Center for the Study of Medicinal
Cannabis and Hemp at Thomas Jefferson University.

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor
grown, pharmaceutical grade cannabis and on the research and development
of novel cannabinoid-based treatments for several central nervous system
disorders, including chronic pain, fibromyalgia and irritable bowel
syndrome. The Company has 25,000 square feet that is licensed at its
Ontario facility and expansion is currently underway.

FSD facilities sit on 70 acres of land with 40 acres primed for
development and an expansion capability of up to 3,896,000 square feet
by 2025.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under
the Cannabis Act and Regulations, having received its cultivation
license on October 13, 2017 and its Sale for Medical Purposes license on
April 18, 2019. FV Pharma’s vision is to transform its current
headquarters in a Kraft plant in Cobourg, Ontario into the largest
hydroponic indoor grow facility in the world. FV Pharma intends to cover
all aspects of this exciting new industry, including cultivation, legal,
processing, manufacturing, extracts and research and development. For
additional information on the company, please visit our website at www.fsdpharma.com.

Forward-Looking Information

Neither the Canadian Securities Exchange nor its regulation services
provider accept responsibility for the adequacy or accuracy of this
release.

Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words “could”,
“intend”, “expect”, “believe”, “will”, “projected”, “estimated” and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information
and are based on FSD Pharma’s current belief or assumptions as to the
outcome and timing of such future events. Actual future results may
differ materially. Actual results and developments may differ materially
from those contemplated by these. The forward-looking information
contained in this press release is made as of the date hereof, and FSD
Pharma is not obligated to update or revise any forward-looking
information, whether as a result of new information, future events or
otherwise, except as required by applicable securities laws. Because of
the risks, uncertainties and assumptions contained herein, investors
should not place undue reliance on forward looking-information. The
foregoing statements expressly qualify any forward-looking information
contained herein.

Contacts

Zeeshan Saeed, President and Founder, FSD Pharma Inc.
Email: [email protected]
Telephone:
(416) 854-8884

Investor Relations
Email: [email protected]
Website:
www.fsdpharma.com

Media
Relations
Ned Berkowitz
Email: [email protected]
Tel:
(646) 942-5629

– Ziva Cooper, Ph.D. and Mallory Loflin, Ph.D. become latest
members of the renowned group of FSD Scientific Advisors led by Charles
Pollack, Jr. MD, FACEP

TORONTO–(BUSINESS WIRE)–#FSDDF–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the
“Company”), is pleased to announce the addition of two
distinguished cannabis researchers to the company’s Scientific Advisory
Board (“SAB”).

“It is with great pride that we welcome Dr. Ziva Cooper and Dr. Mallory
Loflin to our Scientific Advisory Board. The board, which also includes
Dr. Daniel Piomelli and Dr. Ryan Vandrey, is shaping into a very robust
body of scientists and researchers under the leadership of my good
friend Dr. Pollack and I commend him for his leadership. We are counting
on the invaluable input of our SAB members as we continue to explore the
value add of potential applications of medicinal grade cannabis and
synthetic cannabinoid pharmaceuticals,” said Dr. Raza Bokhari, FSD
Executive Co-Chairman & Chief Executive Officer.

Ziva Cooper, Ph.D., is the Research Director of UCLA’s Cannabis Research
Initiative in the Semel Institute for Neuroscience and Human Behavior in
the Department of Psychiatry and Biobehavioral Sciences. Dr. Cooper has
been overseeing and publishing studies investigating cannabis
neurobiology and dependence for over 10 years, including studies
examining the effects of these drugs on experimentally induced
pain. After receiving her Ph.D. in Biopsychology in 2007 in the field of
preclinical psychopharmacology, she moved to Columbia University to
focus on translating preclinical studies of psychoactive substances to
the clinic using controlled human drug-administration studies. Dr.
Cooper’s current research involves understanding the neurobiological,
pharmacological, and behavioral variables that influence both the
therapeutic potential and adverse effects of cannabis and cannabinoids.
She previously served on the National Academies of Sciences Committee on
the Health Effects of Cannabis that recently published a comprehensive
consensus report of the health effects of cannabis and cannabinoids. Dr.
Cooper is a member of the Editorial Board of Cannabis and
Cannabinoid Research.

Mallory Loflin, Ph.D., is a research scientist for Veterans Affairs San
Diego Healthcare System (VASDHCS) and an Assistant Professor of
Psychiatry within the University of California, San Diego (UCSD) School
of Medicine. Dr. Loflin’s entire research career has been dedicated to
the study of cannabinoids, with the aim of informing both prevention
efforts for problematic use and development of cannabinoid-based
therapeutics. She is currently conducting as Principal Investigator
(PI) the first VA-funded cannabinoid clinical trial, “Cannabidiol as an
Adjunctive to Prolonged Exposure for the Treatment of PTSD,” as part of
a Career Development Award (CDA-2) funded by VA Clinical Science
Research & Development (CSR&D). Dr. Loflin is also a co-investigator and
consultant on four other ongoing cannabis and cannabinoid research
studies, and currently holds a DEA research registration for schedule 1
controlled substances at VA San Diego. She is currently engaged in
training efforts for advanced specialization in private-public drug
development as part of her CDA-2 award’s training plan.

The SAB is led by Chairman Charles V. Pollack, Jr., M.A., M.D., FACEP,
FAAEM, FAHA, FACC, FESC, FCPP, an international leader in emergency
medicine and founder of The Lambert Center for the Study of Medicinal
Cannabis and Hemp at Thomas Jefferson University.

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor
grown, pharmaceutical grade cannabis and on the research and development
of novel cannabinoid-based treatments for several central nervous system
disorders, including chronic pain, fibromyalgia and irritable bowel
syndrome. The Company has 25,000 square feet that is licensed at its
Ontario facility and expansion is currently underway.

FSD facilities sit on 70 acres of land with 40 acres primed for
development and an expansion capability of up to 3,896,000 square feet
by 2025.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under
the Cannabis Act and Regulations, having received its cultivation
license on October 13, 2017 and its Sale for Medical Purposes license on
April 18, 2019. FV Pharma’s vision is to transform its current
headquarters in a Kraft plant in Cobourg, Ontario into the largest
hydroponic indoor grow facility in the world. FV Pharma intends to cover
all aspects of this exciting new industry, including cultivation, legal,
processing, manufacturing, extracts and research and development. For
additional information on the company, please visit our website at www.fsdpharma.com.

Forward-Looking Information

Neither the Canadian Securities Exchange nor its regulation services
provider accept responsibility for the adequacy or accuracy of this
release.

Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words “could”,
“intend”, “expect”, “believe”, “will”, “projected”, “estimated” and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information
and are based on FSD Pharma’s current belief or assumptions as to the
outcome and timing of such future events. Actual future results may
differ materially. Actual results and developments may differ materially
from those contemplated by these. The forward-looking information
contained in this press release is made as of the date hereof, and FSD
Pharma is not obligated to update or revise any forward-looking
information, whether as a result of new information, future events or
otherwise, except as required by applicable securities laws. Because of
the risks, uncertainties and assumptions contained herein, investors
should not place undue reliance on forward looking-information. The
foregoing statements expressly qualify any forward-looking information
contained herein.

Contacts

Zeeshan Saeed, President and Founder, FSD Pharma Inc.
Email: [email protected]
Telephone:
(416) 854-8884

Investor Relations
Email: [email protected]
Website:
www.fsdpharma.com

Media
Relations
Ned Berkowitz
Email: [email protected]
Tel:
(646) 942-5629